A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

NCT02521441 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Neutropenia

Interventions

BIOLOGICAL: F-627
BIOLOGICAL: Filgrastim

Sponsor

EVIVE Biotechnology

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]